NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
Data presented at the IASLC 2026 World Conference on Lung CancerPARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilitie…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.